“Electronic Nose” Predicts Immunotherapy Response
An “electronic nose,” or eNose, accurately predicted whether patients with advanced non–small cell lung cancer would respond to anti–programmed cell death 1 (anti-PD-1) therapies in a recent observational study published in the Annals of Oncology. If the findings bear out in randomized clinical…